-
Professor Apolo Discusses the Addition of Adjuvant Immunotherapy for Urothelial Carcinoma in the AMBASSADOR Study | 2024 ASCO-GU Conference
Based on the CheckMate -274 study, nivolumab became the world’s first approved immunotherapy for adjuvant treatment of urothelial carcinoma, while the IMvigor 010 did not achieve positive DFS results, leading to the subsequent focus on ctDNA (MRD) positive patients in the IMvigor 011 study. At the recent 2024 ASCO-GU conference, the results of the pembrolizumab…
-
Professor Chuanliang Cui Interprets the Key Updates of the Urothelial Carcinoma Guidelines | 2024 CSCO Guidelines Conference
Urothelial carcinoma is one of the most common malignant tumors in the urinary system, and its treatment strategies have undergone many changes in recent years. Although traditional chemotherapy has played a significant role in the treatment of urothelial carcinoma, the development of new drugs such as immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) has…
-
Impact of β-Lactam Antibiotics on Gut Microbiota – – Interview with Prof. Etienne RUPPÉ
Prof. Etienne Ruppé, a professor of bacteriology at the Université Paris Cité and researcher at the IAME unit, is conducting a study on the impact of β-lactam antibiotics on the gut microbiota. His research primarily focuses on ceftriaxone, piperacillin-tazobactam, and ceftazidime-avibactam, uncovering significant findings regarding the differential impacts and lasting effects of these antibiotics on…
-
Advances in Endocarditis Diagnosis – An In-Depth Interview with Dr. Maria Nazarena Pizzi
In the dynamic field of infectious diseases, guidelines must adapt to reflect ongoing research and technological advancements to ensure the highest standards of patient care. The 2023 European Society of Cardiology (ESC) Guidelines for the diagnosis of endocarditis mark a significant advancement in how clinicians approach this complex disease. To gain deeper insights into these…
-
EBMT Interview | The Latest Advances and Challenges in Bispecific Antibody Treatment for Lymphoma
Monoclonal antibody-based targeted therapy has significantly improved treatment options for cancer patients. In recent years, advancements in protein engineering have led to the development of bispecific antibodies (BsAbs), marking a paradigm shift in antibody construction usage. BsAbs, recognized for their higher therapeutic response, resistance barrier, and fewer adverse reactions, have caught significant attention in the…
-
EBMT Spotlight Interview | Professor Li Chunfu: Improved TCRαβ-T Cell Depleted Hematopoietic Stem Cell Transplantation (TDH) for Treating Severe Thalassemia
Hematopoietic stem cell transplantation is a common and effective treatment in the field of hematology. As techniques have matured, stem cell transplantation not only serves as a treatment for malignant blood diseases such as leukemia but also offers a new solution for curing thalassemia. The 50th European Society for Blood and Marrow Transplantation (EBMT) Annual…
-
Professor Jun Lu：Metagenomic Next-Generation Sequencing for Detection of False Positive HIV Nucleic Acid Tests in Pediatric Patients Post-CAR-T Treatment: A Case Report
Lentiviral vectors are commonly used in engineering CAR-T cells; however, they can sometimes lead to false positive results for Human Immunodeficiency Virus (HIV) following CAR-T infusion. Identifying such false positives can be challenging.
-
Dr. Thomas Powles: ADC combined with immunotherapy promises to reshape the treatment landscape for urothelial cancer
Oncology Frontier: Currently, platinum-based combination chemotherapy is still the first-line standard treatment for advanced UC. What unmet needs do you think exist for patients with advanced UC? Dr. Thomas Powles:…
Connecting Medical Expertise through Media